Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on July 18, 2012, by Emergent BioSolutions Inc. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing LLC, a wholly-owned subsidiary, with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to the contract modification:
- Contract Value Increase: Approximately $38 million.
Material Changes
The primary material change is the modification of a contract originally dated July 13, 2010. Key changes include:
- Scope Expansion: The modification exercises options for biologics licensing application activities, as well as clinical, feasibility, and stability studies.
- Project Focus: Large-scale manufacturing of BioThrax at the Lansing, Michigan facility.
- Timeline Extension: The contract period of performance was extended to September 30, 2014.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the description of the contract modification. No unusual items were reported.
Key Facts for Investor Verification
- Verify the specific terms and payment milestones associated with the $38 million contract increase.
- Confirm the status of the BioThrax manufacturing facility in Lansing, Michigan.
- Review the requirements for the biologics licensing application and clinical studies to assess potential regulatory hurdles.
- Check subsequent filings for revenue recognition related to this contract extension.